Centre Hospitalier de Saint-Denis
Saint-Denis, 93200, France
Location contact
Stéphanie COSSEC
CONTACT
0142356140 ext. 6962
Yacine Tandjaoui-Lambiotte, Principal Investigator
CONTACT
NCT Number: NCT07679789
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Trial opening soon.
Get NotifiedAll sexes
Observational
Saint-Denis, 93200, France
Stéphanie COSSEC
CONTACT
0142356140 ext. 6962
Yacine Tandjaoui-Lambiotte, Principal Investigator
CONTACT
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: January 2015 to December 2025
Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.
Time frame: From hospital admission through hospital discharge (up to 90 days)
Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.
Time frame: Baseline (at the time of pneumonia diagnosis)
Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.
Time frame: Baseline (at the time of PCR testing)
Proportion of patients with concomitant viral infection identified by microbiological testing.
Time frame: Baseline (at the time of PCR testing)
Proportion of patients with concomitant bacterial infection identified by microbiological testing.
Time frame: From hospital admission through hospital discharge (up to 90 days)
Duration of hospitalization among admitted patients.
Contact information is provided by the study sponsor or research team.
Clinical Research Unit Coordinator Clinical Research Unit Coordinator, GHT Plaine de France Clinical
CONTACT
+33 1 42 35 61 40 ext. 6962
Yacine Tandjaoui-Lambiotte, Principal Investigator
CONTACT
Centre Hospitalier de Saint-Denis
Other
Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR
Acronym: CHLAMPAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07278700
Acute Respiratory Infections, Body Temperature Changes
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04089787
Bacterial Infections, Bacterial Infections and Mycoses
Aalborg, Denmark
View Trial DetailsNCT07357935
Acute Respiratory Failure, Community-Acquired Infections
View Trial DetailsNCT07279675
Community-Acquired Infections, Community-Acquired Pneumonia
View Trial Details